The U.S. rig count saw a marginal increase this week, yet remains significantly below last year's levels as crude production dips and completions activity sends conflicting signals.
Campbell Soup Company will shutter its Hyannis, Massachusetts facility, the original home of Cape Cod Potato Chips, citing economic inefficiency. The closure, affecting 49 jobs, marks a strategic shift of production to larger plants as the snack giant consolidates its network.
Advocate Health, the nation's third-largest nonprofit health system, is investing over $800 million in enhanced compensation and benefits for its 165,000+ employees, raising its minimum wage and expanding tuition aid, mental health support, and paid volunteer time.
Profitability alone is no longer a reliable indicator of future success. In today's competitive landscape, companies must balance healthy margins with sustainable growth. We analyze one firm positioned to do just that, and two where investors should look deeper.
Mid-cap companies offer a compelling blend of established operations and growth runway, but they navigate a perilous landscape between industry titans and agile disruptors. We examine three stocks where investor optimism may be overlooking critical challenges.
Analyst sell ratings are rare on Wall Street, making them noteworthy when they appear. We examine one such case where pessimism may have gone too far, creating a potential opportunity, alongside two stocks where the cautious outlook appears justified.
While small-cap stocks can offer unique growth opportunities away from Wall Street's spotlight, their inherent risks demand careful scrutiny. We examine three companies where valuation concerns and competitive pressures suggest caution may be warranted.
While the allure of finding the next undervalued gem is strong, some stocks trading at low multiples may be cheap for a reason. We examine three companies where fundamental challenges could outweigh their seemingly attractive valuations.
The fourth-quarter earnings season for diversified banks revealed a tale of divergence. While PNC Financial surprised to the upside, industry titan Citigroup fell short of expectations, highlighting the uneven pressures facing the sector.
As earnings season winds down, the waste management sector reveals a tale of resilience and regulatory reckoning. While Enviri's results disappointed, others like Perma-Fix surprised to the upside, highlighting the industry's complex dance between steady demand and economic sensitivity.
The third-quarter earnings season reveals a tale of two strategies in the property services sector. While Opendoor stumbles amid a major strategic shift, peers like Howard Hughes Holdings post surprising strength, highlighting the industry's uneven adaptation to a higher-rate environment.
Waste Management's fourth-quarter revenue fell short of Wall Street forecasts, yet the company demonstrated robust margin expansion through disciplined cost management and strategic integration of acquisitions, setting a firm foundation for its 2026 outlook.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
Boston Scientific (BSX) is attracting bullish analyst attention after its strategic acquisition of Penumbra, with Truist Securities reiterating a Buy rating and a $120 price target, citing enhanced business durability and growth prospects.
DexCom Inc. (DXCM) has released preliminary Q4 figures that exceeded expectations and provided robust long-term guidance, reinforcing its position as a favored pick among analysts and hedge funds in the medical devices sector.
Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.
Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.
A recent physician survey on renal denervation procedure volumes has prompted analysts to adopt a more measured view of Medtronic's near-term growth potential, even as the medical device giant remains a favored long-term holding.
Weekly unemployment filings in New York state rose last week, contrasting with a slight national decline and highlighting regional economic disparities.
A.O. Smith's Q4 2025 earnings reveal a tale of two stories: revenue that missed expectations but profits that beat them. The water technology leader is leaning into commercial strength and operational discipline to expand margins, even as it braces for a challenging 2026 marked by input cost inflation and persistent softness in its China business.
